• ALung Technologies

  Participated · Series B · Sep 2013

  ALung Technologies develops the Hemolung Respiratory Assist System (RAS), a minimally invasive artificial lung that removes carbon dioxide independently of the lungs using a process called Respiratory Dialysis®. The company focuses on low‑flow extracorporeal carbon dioxide removal (ECCO2R) to treat patients with acute respiratory failure. The Hemolung RAS has been used to treat hundreds of patients outside the United States since 2013 and received FDA Expedited Access Pathway designation in 2015. ALung plans to use new funding to support a U.S.‑based pivotal clinical trial aimed at FDA approval and broader availability in the United States. The company is privately held and headquartered in Pittsburgh; it was founded in 1997. The recent financing strengthens clinical and commercialization plans while adding strategic partners to its board and advisory ranks. ALung Technologies is a privately held Pittsburgh-based developer and manufacturer of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies, notably the Hemolung RAS which uses a Respiratory Dialysis® process. The Hemolung RAS is positioned as a dialysis-like alternative or supplement to mechanical ventilation for acute respiratory failure, with applications in ARDS and COPD. The company reports CE mark clearance in 2013, global clinical adoption at leading centers, and that hundreds of patients have been treated with the technology. ALung is pursuing a share of the estimated $6 billion acute respiratory failure market. The company plans to use recent financing to support continued commercialization and to complete work required to obtain IDE approval for a U.S.-based clinical trial following its Expedited Access Pathway (EAP) designation. ALung was founded in 1997 and is backed by individual investors and venture firms named in its filings. ALung Technologies develops and manufactures the Hemolung Respiratory Assist System (RAS), a low‑flow, minimally invasive extracorporeal carbon dioxide removal (ECCO2R) device. The Hemolung provides Respiratory Dialysis® as an alternative or supplement to mechanical ventilation with indications including acute exacerbation of COPD and ARDS. The device was tested at 43 hospitals in 13 countries and following a successful clinical trial in Germany received regulatory clearances in Europe and Canada. ALung initiated a controlled launch in mid‑2013 and has accelerated commercial roll‑out in Germany, the UK, France, Canada, and Australia. The Hemolung RAS is currently approved in 29 countries across Europe, the Middle East, and Asia‑Pacific. The company says it will use new financing to accelerate global commercialization of the technology. ALung Technologies develops extracorporeal respiratory assist devices, principally the Hemolung Respiratory Assist System (RAS), a dialysis-like extracorporeal carbon dioxide removal (ECCO2R) system. The Hemolung RAS provides Respiratory Dialysis® as a simple, minimally invasive alternative or supplement to mechanical ventilation and has indications for ARDS and acute exacerbation of COPD. The device is approved for sale in Europe and Canada, and ALung has established direct commercial operations in Germany, France, and the United Kingdom while entering additional markets through distribution partners. The company intends to use new capital to support global commercialization and to further develop next-generation products and platform technologies for less-invasive extracorporeal lung support. To date ALung has raised $56 million in equity capital, and the recent financing will primarily support the global launch of the Hemolung RAS. ALung's lead product, HemoLung, is an extracorporeal artificial lung that removes carbon dioxide from blood while infusing oxygen via a catheter into the femoral or jugular vein. The device is intended for patients with acute respiratory failure to help them avoid mechanical ventilation. Four months after receiving CE Mark approval, ALung is commercializing HemoLung in Germany, France, the UK and Canada and plans sales in Canada and Australia. The company has set up 10 reference centers, is hiring clinical specialists and support staff, and is seeking distributors in Europe, Canada and Australia. ALung estimates a patient population of about 900,000 and a market opportunity of roughly $4.6 billion. The company was started in 1997 by Dr. Brack Hattler and Bill Federspiel.

• ShowClix

  Participated · Series B · Mar 2011

  ShowClix is a cloud-based event technology platform that provides full-service ticketing, access control, and on-site support for professional event organizers. The company offers a tailored platform supported by dedicated client success managers, an in-house call center, marketing support, and experienced on-site teams. ShowClix has introduced industry innovations such as the first iOS ticket scanner, a handheld RFID admissions solution, an automated digital assistant called Agent, and recently launched analytical tools to help organizers manage engagement and grow their business. Founded in 2007, the platform has processed over a billion dollars in ticket sales across 37 countries. The company intends to continue product innovation and expand into new markets, leveraging partnerships to accelerate growth. ShowClix provides venues, promoters and event organizers with solutions to manage all aspects of their ticketing operations, including online and telephone ticket sales, box office management, admissions control, and event promotion. Led by CEO Joshua Dziabiak, the company works with over 1,800 live music venues, performing arts groups, museums, festivals, nightclubs, artist management companies, non-profit organizations and colleges and universities around the world. It recently signed a strategic partnership with Groupon and added The Museum of Modern Art in New York City, Lucas Oil Speedway and Val-Du-Lakes Pavilion to its client portfolio. The company has raised a $1.65M Series B and intends to use the funding to expand sales, marketing and product development. Harris Jones, Managing Partner of Swallow Point Ventures and former CEO of T-Mobile UK, will join the company's board in conjunction with the financing. ShowClix provides web-based solutions to event organizers, promoters and venue managers across the U.S., enabling online, telephone, and in-person ticket sales through a point-of-sale/box-office system. The company serves performing arts centers, nightclubs, live music venues, non-profit organizations, and other event operators. It recently completed a Series A and plans to use the funds to expand staff, boost sales and marketing efforts, and extend customer support. ShowClix competes in a multi-million-dollar market and faces stiff competition from TicketMaster and other ticketing providers. Financially, the Series A amount was not formally disclosed; an SEC filing showed $570,000 of an $850,000 round early on, and co-founder Joshua Dziabiak later said the round totaled between $750,000 and $1.5M. The company had earlier raised about $400,000 in seed funding from Innovations Works.

No current team members are available.